Literature DB >> 30442097

Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma.

Magda Zanelli1, Maria Cecilia Mengoli1, Rachele Del Sordo2, Angelo Cagini2, Loredana De Marco1, Edoardo Simonetti3, Giovanni Martino3, Maurizio Zizzo4,5, Stefano Ascani6.   

Abstract

BACKGROUND: Intravascular lymphoma is a rare type of non-Hodgkin lymphoma mostly of B-cell lineage. A few cases of intravascular lymphoma have been found to be of NK/T-cell origin, mainly affecting the skin and central nervous system. CASE
PRESENTATION: A 54-year-old Caucasian man sought care because of a 2 weeks history of jaundice and intermittent fever, not responsive to antibiotics and antipyretics. Laboratory tests showed low blood oxygen concentration and pancytopenia. Serum microbiological tests were negative. Computerized tomography (CT) scan revealed hepatosplenomegaly and diffuse ground-glass opacities in both lungs without interlobular septal thickening. Despite oxygen therapy, the clinical conditions rapidly deteriorated leading to death 3 days after admission. Autopsy revealed a multiorgan involvement by an Epstein-Barr virus positive NK/T-cell lymphoma, strikingly growing within the blood vessel lumina, in absence of skin lesions.
CONCLUSIONS: The current case highlights the pathological features of this rare entity, the protean clinical presentation of which is often misleading, resulting in delayed diagnosis and treatment.

Entities:  

Keywords:  Epstein-Barr virus; Intravascular; Lymphoma; Natural killer cell; T-cell

Mesh:

Year:  2018        PMID: 30442097      PMCID: PMC6238309          DOI: 10.1186/s12885-018-5001-6

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


Background

Intravascular lymphoma (IVL) represents a rare neoplasm in which the tumor cells are confined to the lumina of blood vessels. Skin and central nervous system (CNS) are most commonly involved, although virtually any organ can be affected [1]. The majority of cases are of B-cell origin [1], however, rare cases of T and natural killer (NK) immunophenotype have been reported [2-18]. IVL of B-cell phenotype are rarely Epstein-Barr virus (EBV) positive [8], whereas the frequent detection of EBV in NK/T cell IVL supports its possible pathogenic role. NK/T-cell IVL differs from nasal-type NK/T-cell lymphoma mainly by its intravascular nature. NK/T-cell IVL is an aggressive neoplasm with a poor outcome, although the prognosis appears to be related to the extent of disease. Herein we report the case of a 54-year-old male with a rapidly progressive course. The clinical picture was somewhat confusing and led the physicians to suspect a generalized sepsis. Autopsy disclosed involvement of multiple organs by IVL NK/T-cell lymphoma, in absence of skin lesions. A review of the reported cases of NK/T-cell IVL with immunohistochemical and molecular data is also performed.

Case presentation

A 54-year-old Caucasian man sought care because of a 2 weeks history of jaundice and intermittent fever (up to 39 °C), not responsive to antibiotics and antipyretics. His past medical records included arterial hyperthension and a left vertebral artery dissection. Upon admission, he was pyretic, jaundiced, tachypneic and lypotimic. No cutaneous lesions were present. Neurological examination was normal. Laboratory tests showed low blood oxygen concentration (pO2 62 mmHg, pCO2 22 mmHg, HCO3 18.8 mmol/L, pH 7.55), anemia (Hb 10.2 g/dL), leukocytopenia (3.100/mcL) and thrombocytopenia (62.000/mcL). Atypical circulating lymphocytes were absent. Increased levels of transaminases (ALT 1374 u/L; AST 654 u/L), gamma-GT (802 u/L) and lactate dehydrogenase (LDH 2998 u/L) were present. Serum microbiological tests were negative. Computerized tomography (CT) scan revealed hepato-splenomegaly and diffuse ground-glass opacities in both lungs without interlobular septal thickening. No lesion was detected in the upper aerodigestive tract. Despite oxygen therapy, the clinical conditions rapidly deteriorated leading to death 3 days after admission. A severe, generalized sepsis was suspected. A total-body autopsy was performed. Gross examination revealed pericardial, pleural and peritoneal effusions. The lungs were heavier than normal (right lung 910 g; left lung 930 g) with multiple foci of consolidation. The spleen was enlarged (610 g) as well as the liver (1920 g), without focal lesions. No lesions were found in the skin, oral cavity or oropharynx. Polymerase chain reaction (PCR) detected about 2 millions copies of EBV DNA on pleural (Fig. 1) effusion and lung tissue.
Fig. 1

EBV DNA detection in pleural effusion by Polymerase chain reaction (PCR)

EBV DNA detection in pleural effusion by Polymerase chain reaction (PCR) Histology revealed atypical lymphoid cells filling and expanding the lumina of small and medium blood vessels (Fig. 2) in virtually any organs (heart, lung, kidney, spleen, liver, brain). A sinusoidal involvement occurred in bone marrow, with about 10% of neoplastic infiltrate. Features of hemophagocytosis (Fig. 2d) were also evident in bone marrow. The lymphoid cells, strikingly confined to the blood vessels lumina, were large-sized with hyperchromatic nuclei and expressed at immunohistochemistry: CD3 (Fig. 3b), CD2, perforin, CD56 (Fig. 3c), granzyme B (Fig. 3d), showing a T and cytotoxic phenotype. CD20, CD79alfa, PAX5, CD4, CD8, CD5, ALK1, CD16 were all negative. Either external or internal positive controls were used to validate the assay for each immunohistochemical staining. The proliferative index (Ki67) was high (approximately of 80%). EBV encoded RNA in situ hybridization (EBER) was diffusely positive (Fig. 3e). Polymerase chain reaction identified a clonal T-cell receptor gamma gene rearrangement (Fig. 4). The final diagnosis was EBV positive intravascular NK/T-cell lymphoma with multisystem involvement.
Fig. 2

Haematoxylin and Eosin, medium power of view of the myocardium (a), of the brain (b) and liver parenchyma (c), show a prominent intravascular growth of neoplastic, pleomorphic cells without invasion of the organs parenchyma characteristic of intravascular lymphoma either of B or NK/T lineage. Immunohistochemistry with CD68 PGM1 (d) of the bone marrow evidence prominent features of haemophagocytotosis

Fig. 3

Haematoxylin and Eosin, medium power of view of the lung parenchyma with striking features of growth of the neoplastic cells within the capillaries of the alveolar walls (a). Immunohistochemistry with CD3 (b), CD56 (c) and granzyme B (d) demonstrate a positive staining of the neoplastic intravascular cells. EBER (e) has been demonstrated also to be diffusely positive in this case of intravascular NK/T lymphoma

Fig. 4

TCR assay provided molecular genetic evidence of clonality. One reproducible clonal peak is showed in TCR-G

Haematoxylin and Eosin, medium power of view of the myocardium (a), of the brain (b) and liver parenchyma (c), show a prominent intravascular growth of neoplastic, pleomorphic cells without invasion of the organs parenchyma characteristic of intravascular lymphoma either of B or NK/T lineage. Immunohistochemistry with CD68 PGM1 (d) of the bone marrow evidence prominent features of haemophagocytotosis Haematoxylin and Eosin, medium power of view of the lung parenchyma with striking features of growth of the neoplastic cells within the capillaries of the alveolar walls (a). Immunohistochemistry with CD3 (b), CD56 (c) and granzyme B (d) demonstrate a positive staining of the neoplastic intravascular cells. EBER (e) has been demonstrated also to be diffusely positive in this case of intravascular NK/T lymphoma TCR assay provided molecular genetic evidence of clonality. One reproducible clonal peak is showed in TCR-G

Discussion and conclusions

IVL are neoplasms, mostly of B-cell phenotype, characterized by the presence of large lymphoid cells strikingly restricted to the blood vessels lumina. Intravascular large B-cell lymphoma is recognized as a distinct lymphoproliferative disorder by World Health Organization (WHO) [1]. Two patterns of presentation have been recognized: a classic, Western variant involving more often skin and CNS and an Asian variant presenting with multiorgan failure, often associated with hemophagocytic syndrome [19]. Cases limited to the skin usually have a better prognosis. IVL of T and NK-cell lineage are exceedingly rare and very few cases have been reported so far [2-18]. NK/T-cell IVL is still not recognized as a specific entity by the last WHO classification of lymphoid neoplasms, probably due to its rarity. Extranodal NK/T-cell lymphoma, nasal-type rarely manifests features of intravascular lymphoma, involving sites such as the skin and CNS [1]. The main differential diagnosis of NK/T IVL includes: extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukaemia, both of which are EBV-related, and primary cutaneous anaplastic CD30 positive T-cell lymphoma. Neoplastic cells are confined within lymphatic vessels in cutaneous anaplastic CD30 positive T-cell lymphoma, its course is indolent and EBER is negative [1]. In nasal-type NK/T-cell lymphoma, the upper aerodigestive tract is the privileged site of involvement, although other extranodal sites, including the skin, have been reported [1]. The neoplastic cells permeate the tissues with angioinvasion and are not limited to the endovascular system. Aggressive NK-cell leukaemia is considered the leukaemic counterpart of nasal-type NK/Tcell lymphoma and a leukemic blood picture is usually present, distinguishing it from intravascular NK/T-cell lymphoma [1]. CD16 positivity is frequently seen in aggressive NK-cell leukemia, whereas both extranodal NK/T-cell lymphoma, nasal-type and intravascular NK/T-cell lymphoma show CD16 negativity, as it was in our case. To the best of our knowledge, only 24 cases of NK/T-cell IVL with sufficient immunohistochemical and molecular data, including the present case, have been reported so far [2-18]. The clinicopathologic features are summarized in Table 1. The patients, 11 males and 13 females, ranged from 18 to 87 years of age. The skin and CNS were frequently involved, although any organ can be affected. The disease often presented with skin lesions (22/24) and in 11 cases the skin was the unique site of involvement. Sharma et al. reported a case presenting with almost unique brain involvement [17]. In 5 patients the disease affected both skin and brain [2, 5, 7, 12, 16]. Neurologic symptoms (depression and dizziness), reflecting possibly brain involvement, occurred in 2 more cases, concurrently with skin lesions [7, 9]. Two patients had skin lesions and manifestations in other organs (ileum plus spleen [6] and liver [14], respectively). In one report, in addition to skin lesions, the patient had portal hypertension of unknown origin, thought to be possibly related to liver involvement [7]. However, in absence of post-mortem examination, it is always presumable that internal organs might have had undetected involvement.
Table 1

Demographic data, clinical data, and characteristics of reported cases of IVL of T and NK-cell lineage

Ref.Age/sexSites involved at presentation/(symptoms/ signs)Sites involved during disease courseBOM involvementImmunophenotypeEBERTCRTherapy/outcome
Santucci 2003 [2]54/MSkin lesions, weight loss, leukopeniaCNSNACD3e + CD56 + TIA-1 + GrB + CD30 + ki671 + 100%LMP1-CD4- CD8- CD20- CD79a- CD57- CD68- Bcl2-+NACHOP/Exitus 17 mo after diagnosis
Wu 2005 [3]41/MSkin lesionsnoneCD3e + CD2 + CD7 + CD56 + CD43 + perforin+ TIA-1 + Bcl2 + CD20- CD4- CD8- CD5- TCRbF1- CD30- lysozyme- MPO- Keratin-+TCR germlineCHOP+SCTCR at 12 mo
Wu 2005 [3]47/FFever, weakness, arthralgia, myalgia, mental signs+ pancytopeniaDisseminated disease at autopsy (brain, bone marrow, kidneys, ovaries, cervix)+ (diagnosis made on BOM biopsy)CD3e + CD2 + CD7 + CD56 + GrB + TIA-1 + CD20- CD5- CD4- CD8- CD57-TCR germlineUnspecified therapy/exitus 15 days after diagnosis
Kuo 2006 [4]71/FSkin lesionsnoneCD3e + CD56 + TIA1 + KI67 + 90%CD4- CD5- CD8- CD10- CD20-CD30- BCL6- LMP-1-+TCR germlineNo therapy/alive at 5 mo
Song 200740/FSkin lesions+CNSnoneLCA + CD3 + CD56+ GrB + TIA + 1+ Ki67 + 100%CD20- CD4- CD8- CD29-+TCR germlineCODOX-M + IVAC/alive at 7mo
Nakamichi 2008 [6]23/FSkin lesionsIleum, spleen+feverCD3e + CD56+TIA1 + ki67 + 100%CD20- CD79a- CD45RO-+TCR germlineCHOP followed by PromMACE/CYTABOM, L-ASP/CY, hyper CVAD/MTX-AraC, SCT. Exitus after 9 mo, due to aGVHD
Cerroni 2008 [7]67/FSkin lesion+CNSnoneNACD2+ CD3e + CD8 + CD56-TIA-1 + CD4- CD20- CD30+/- CD56-NATCR monoclonal (TCRg)Exitus after 7 days
Cerroni 2008 [7]63/MSkin lesions+arthralgias, weight loss, fever, depression+leukopenia+ thrombocytopenianoneNACD2 + CD3e + TIA1 + CD56+ CD4- CD5- CD7- CD8- CD20- CD45RO + bF1-+TCR germlineExitus after 6 mo
Cerroni 2008 [7]64/M(History of B-CLL). Skin lesionsNA- (B-CLL+)CD2 + CD3e + TIA-1 + CD4- CD5- CD8- CD20- CD56- bF1-TCR germlineCHOP, exitus after 7 mo
Cerroni 2008 [7]87/MSkin lesions+portal hyperthensionnoneNACD2 + CD3e + CD56- TIA-1- GrB-perforin- CD4- CD5- CD7- CD8-CD20- CD30- CD45RO- bF1-+TCR monoclonal (TCRg)Exitus after 15 days
Gleason 2008 [8]62/MSkin lesions+night sweatsnoneLCA + CD2 + CD3e + CD43 + CD56 + Perforin+ GrB + TIA-1 + CD4- CD5- CD7- CD8- CD20- CD79a- BCL2- CD30- CD45RO- TCRbF1- TdT- MPO- CK- CD34-TCR monoclonal(TCRg)CHOP followed by DHAP. AWD at 8 mo
Liao 2011 [11]42/FSkin lesions+ malaise, dizziness.noneCD3e + CD56 + Gr-B + KI67 + 99%,bF1- CD4- CD5- CD8- CD20- CD30- PAX5- TdT-+NART + CT: (CHOP,Bortezomib, EPOCH); alive at 14 mo
Yanning 201384/FSkin lesions+fever, weight lossNANACD2 + CD3e + CD45RO + GrB + CD4- CD5- CD7- CD8- CD20- CD79a- CD56- CD30- panCK-+TCR germlineTherapy refused. AWD at 4 mo
Jang 201423/FSkin lesionsnoneCD3 + CD8 + GrB + TIA-1 + LCA + MPO + CD4- CD5- CD20- CD30- CD56- CK-+TCR germlineIgH gene clonalCHOP+intratecal MTX + PBSCT.Skin recurrence followed by unspecified CT. Exitus 11 mo after recurrence
Liu 201438/FSkin lesionsCNSCD3 + CD56 + GrB + Ki67 + 90%CD4- CD5- CD8- CD20- CD30- PAX5- TdT-+NACHOP. After 7 mo recurrence at CNS. Exitus 13 mo after diagnosis
Wang 201545/MSkin lesions+malaise, fever, weight lossNANACD2 + CD3e + perforin+ GrB + TIA1 + CD56 + CD4- CD8- CD20- TCRb- TCRg- CD30- KI67 + 90–100%+TCR germlineExitus 15 days after diagnosis
Wang 201532/FSkin lesions+fevernoneNACD2 + CD3e + perforin+ GrB + TIA1 + CD56 + CD4- CD8- CD20- TCRb- TCRg- CD30- KI67 + 90–100%+TCR germlineCHOP. Exitus 4 mo after diagnosis
Wang 201518/FSkin lesionsnoneCD2 + CD3e + perforin+ GrB + TIA1 + CD56 + CD4- CD8- CD20- TCRb- TCRg- CD30 + KI67 + 90–100%+TCR germlineCHOP. Alive 3 yrs. after diagnosis
Bi 201529/MSkin lesions, fever, weight lossLiverCD3 + CD43 + CD56 + TIA-1 + CD30 + CD4- CD5- CD7- CD8- CD20- CD79a- KI67 + 90%+TCR germlineHyperCVAD. Exitus 3 mo after diagnosis
Alhumidi 201548/FSkin lesionsNoneCD45 + CD3 + GrB + CD56- CD4- CD5- CD8- CD20-+NACT. Alive 18 mo after diagnosis
Jaffe 201751/MSkin lesions+CNSnoneNACD3 + CD8 + TIA-1 + GrB + CD20- CD79a- CD56- ALK-1-+TCR monoclonal (TCR-g)NA
Sharma 201762/FCNSnone+ on molecular analysis (TCR)CD3 + CD8 + CD57 + GrB + TIA-1 + CD2- CD4- CD5- CD7- CD30- CD56- TdT- PAX5-TCR monoclonalMethylprednisolone, dexamethasone, intratechal MTX, cytarabine. Exitus
Alegria-Landa 201781/MSkin lesionsnoneCD3 + GrB + perforin+ CD30 + CD20- CD4- CD8- TCRb- TCRg- CD56-+TCR monoclonal (TCRbTCRg)Exitus 15 days after diagnosis
Present case54/MJaundice, fever, respiratory symptoms, pancytopenia. PB: no atypical lymphocytesDisseminated disease at autopsy (brain, heart, kidney, lung, bone marrow)+ (subtle infiltration)CD3 + CD2 + perforin+ GrB + CD56 + KI67 + 80% CD20- CD79a- PAX5- CD4- CD8- CD5- ALK1-CD16-+TCR monoclonalExitus 18 days after presentation

Ffemale, M male, BOM bone marrow, NA not assessed, CR complete remission, mo months, yrs. years, B-CLL B chronic lymphocytic leukemia, RT radiotherapy, CT chemotherapy, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, SCT Stem cell transplant, CODOX-M cyclophosphamide, vincristine, doxorubicin, methotrexate, IVAC ifosfamide, mesna, etoposide, cytarabine, ProMACE/CytaBOM prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytosine, arabinoside, bleomycin, vincristine, leucovorin, l-ASP l-asparaginase, CY cyclophosphamide, hyper-CVAD hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, MTX methotrexate, AraC cytosine arabinoside, aGVHD acute graft-versus-host disease, EPOCH etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, DHAP dexamethasone, cytarabine, cisplatin, PBSCT peripheral blood stem-cell transplant, PB peripheral blood, AWD alive with disease

Demographic data, clinical data, and characteristics of reported cases of IVL of T and NK-cell lineage Ffemale, M male, BOM bone marrow, NA not assessed, CR complete remission, mo months, yrs. years, B-CLL B chronic lymphocytic leukemia, RT radiotherapy, CT chemotherapy, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, SCT Stem cell transplant, CODOX-M cyclophosphamide, vincristine, doxorubicin, methotrexate, IVAC ifosfamide, mesna, etoposide, cytarabine, ProMACE/CytaBOM prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytosine, arabinoside, bleomycin, vincristine, leucovorin, l-ASP l-asparaginase, CY cyclophosphamide, hyper-CVAD hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, MTX methotrexate, AraC cytosine arabinoside, aGVHD acute graft-versus-host disease, EPOCH etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, DHAP dexamethasone, cytarabine, cisplatin, PBSCT peripheral blood stem-cell transplant, PB peripheral blood, AWD alive with disease Wang et al. [13] reported 5 cases of NK/T-cell IVL, but, as commented by Alegria-Landa et al. [8] in 2017, the possibility of an extranodal NK/T-cell lymphoma nasal-type in their case number 2 cannot be excluded. As well in their case number 5, the presence of circulating atypical CD56 positive lymphocytes, makes aggressive NK leukemia the most likely diagnosis. In the present review these 2 cases have been discounted. Protean clinical findings, including fever, malaise, weight loss, arthralgia, night sweats and jaundice were reported half of time (11 cases). The confusing clinical picture might be misleading, as demonstrated in the current case, compromising a prompt diagnosis and treatment. Hematologic findings, including leukopenia, thrombocytopenia, pancytopenia occurred in 4 patients as well as in our case [2, 3, 7]. Bone marrow involvement is uncommon, being detected in 3/16 evaluated, including the present report [3, 17]. In the case by Wu et al. the diagnosis was made on bone marrow biopsy in a 47-year-old female with protean systemic and neurological symptoms [3]. As Wu et al. pointed out the lymphomatous sinusoidal infiltrate in bone marrow might be subtle (as in our case) and detected only by immunohistochemical staining [3]. In the case of Sharma et al. bone marrow involvement was identified only by molecular studies showing a clonal T-cell population [17]. Clinically our case shows some similarities with case number 2 reported by Wu [3]. In both cases skin lesions were strikingly absent (differently from all the other cases reported) and the disease was widely disseminated at presentation, as confirmed at post mortem examination. A subtle bone marrow involvement was identified in both cases. In addition, in the present report features of hemophagocytosis were also evident. In both cases the disease’s course was rapid and fatal. Most NK/T-cell IVL share a common profile with a cytotoxic phenotype (CD56 and cytotoxic molecules positivity), although the expression of individual immunohistochemical markers may change from case to case. A strong association with EBV was evident as EBER positivity was detected in 19 out of 23 tested diseases. The frequent association with EBV infection underlines the similarities with NK/T-cell lymphoma nasal-type. Thirteen of 20 evaluated cases had a germline configuration of TCR gene. In the remaining 7 cases, including the present report, a monoclonal TCR gene rearrangement was identified. As already mentioned, NK/T-cell IVL can be difficult to diagnose due to its multifaceted clinical presentation. It can involve any organ, although more frequently CNS and skin. In addition to non-specific symptoms (fever, weight loss, malaise), patients commonly present skin lesions (as erythematous, indurated plaques and nodules) and often bizarre neurologic symptoms, caused by multiple sites of infarct resulting from vascular occlusion. The pathological diagnosis of NK/T-cell IVL can be established by combined histopathologic, immunohistochemical and molecular studies. However, it has to be stressed that, in case of a small number of neoplastic cells in vessels, NK/T-cell IVL can be easily overlooked. Therefore, a strict clinicopathological correlation is essential to get to a prompt diagnosis. NK/T-cell IVL often follows an aggressive clinical course, however, the prognosis may vary with the extent of disease, being more favorable in patients with exclusive skin lesions. In particular 2 cases with the disease limited to the skin had a really favorable outcome, being in complete remission after 1.5 and 3 years [13, 15]. However, the limited number of cases makes difficult to draw any conclusion. The literature data suggest that CHOP regimen is insufficient for the treatment of NK/T-cell IVL, whereas a combination of intensive chemotherapy often anthracycline-based and stem cell transplantation may improve the outcome [6, 12]. In summary, presenting this case of NK/T-cell IVL with multiorgan involvement and lacking the more common skin presentation, we would like to draw attention on a very rare entity of which both clinicians and pathologists should be aware. As the clinical picture can be very misleading, a high level of suspicion is essential to achieve a prompt diagnosis.
  18 in total

1.  Intravascular large cell lymphoma of the natural killer cell type.

Authors:  Dong Eun Song; Mi-Woo Lee; Min-Hee Ryu; Dong Wha Kang; Sang Joon Kim; Jooryung Huh
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

2.  Intravascular NK/T-cell lymphoma: a report of five cases with cutaneous manifestation from China.

Authors:  Lei Wang; Siyuan Chen; Han Ma; Dongmei Shi; Changzheng Huang; Chun Lu; Tianwen Gao; Gang Wang
Journal:  J Cutan Pathol       Date:  2015-05-29       Impact factor: 1.587

Review 3.  NK-cell intravascular lymphomatosis--a mini-review.

Authors:  Naoto Nakamichi; Shirou Fukuhara; Katsuyuki Aozasa; Eiichi Morii
Journal:  Eur J Haematol       Date:  2008-05-06       Impact factor: 2.997

4.  Intravascular large cell lymphoma of NK/T-cell type, EBV positive.

Authors:  Linda Okonkwo; Elaine S Jaffe
Journal:  Blood       Date:  2017-08-10       Impact factor: 22.113

5.  Cutaneous intravascular NK-cell lymphoma.

Authors:  Xue Yanning; Hao Chen; Haipeng Si; Yan Liu; Zhongsheng Min
Journal:  Eur J Dermatol       Date:  2013-04-01       Impact factor: 3.328

Review 6.  Cutaneous intravascular NK-cell lymphoma: report of a rare variant associated with Epstein-Barr virus.

Authors:  Tseng-tong Kuo; Ming-Jing Chen; Ming-Chung Kuo
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

7.  First reported cases of intravascular large cell lymphoma of the NK cell type: clinical, histologic, immunophenotypic, and molecular features.

Authors:  Huiqing Wu; Jonathan W Said; Elizabeth D Ames; Chen Chen; Valerie McWhorter; Peter Chen; Violette Ghali; Geraldine S Pinkus
Journal:  Am J Clin Pathol       Date:  2005-04       Impact factor: 2.493

8.  Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.

Authors:  Andrés J M Ferreri; Giuseppina P Dognini; Elías Campo; Rein Willemze; John F Seymour; Osnat Bairey; Maurizio Martelli; Amalia O De Renz; Claudio Doglioni; Carlos Montalbán; Alberto Tedeschi; Astrid Pavlovsky; Sue Morgan; Lilj Uziel; Massimo Ferracci; Stefano Ascani; Umberto Gianelli; Carlo Patriarca; Fabio Facchetti; Alessio Dalla Libera; Barbara Pertoldi; Barbara Horváth; Arpad Szomor; Emanuele Zucca; Franco Cavalli; Maurilio Ponzoni
Journal:  Haematologica       Date:  2007-04       Impact factor: 9.941

9.  Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection.

Authors:  Lorenzo Cerroni; Cesare Massone; Heinz Kutzner; Thomas Mentzel; Pablo Umbert; Helmut Kerl
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

10.  Intravascular cytotoxic T-cell lymphoma in a young immunocompetent woman.

Authors:  Yong Hyun Jang; Seok-Jong Lee; Yoon Hyuk Choi; Weon Ju Lee; Do Won Kim; Jeongshik Kim; Tae In Park; Yee Soo Chae
Journal:  Ann Dermatol       Date:  2014-07-31       Impact factor: 1.444

View more
  10 in total

1.  Nasal NK/T cell lymphoma mimicking mucosa-associated lymphoid tissue lymphoma in morphology: A case report.

Authors:  Guohua Yu; Xiaoqian Liu; Huihui Zhou; Licai An; Hongyan Li; Shishou Wu; Yinghui Liu; Xubo Pan; Guimei Qu; Xiaoxia Chu
Journal:  Oncol Lett       Date:  2019-09-13       Impact factor: 2.967

Review 2.  Primary Pulmonary B-Cell Lymphoma: A Review and Update.

Authors:  Francesca Sanguedolce; Magda Zanelli; Maurizio Zizzo; Alessandra Bisagni; Alessandra Soriano; Giorgia Cocco; Andrea Palicelli; Giacomo Santandrea; Cecilia Caprera; Matteo Corsi; Giulia Cerrone; Raffaele Sciaccotta; Giovanni Martino; Linda Ricci; Francesco Sollitto; Domenico Loizzi; Stefano Ascani
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

3.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

4.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Magda Zanelli; Maria Paola Bonasoni; Loredana De Marco; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Maria Carolina Gelli; Alessandro Tafuni; Moira Ragazzi
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

Review 5.  [Clinicopathological features of intravascular peripheral T-cell lymphoma].

Authors:  X Guan; Y C Yang; Y Qi; W C Gong; X Y Xu; Y L Wang; Y H Guo; Y Luo; L Sun; K Fu; B Meng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-07-14

6.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Davide Nicoli; Enrico Farnetti; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

7.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Daniel Athanazio; Jatin Gandhi; Alberto Cavazza; Giacomo Santandrea; Alessandro Tafuni; Magda Zanelli
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

8.  Orbital Intravascular Natural Killer/T-cell Lymphoma: An Unusual Cause of Ocular Symptoms.

Authors:  Naohiro Uchio; Daiki Yashita; Akihito Hao; Atsuhito Nakayama; Shigeki Morita; Tsuyoshi Takahashi; Masaya Mori; Hideyuki Matsumoto
Journal:  JMA J       Date:  2022-06-17

9.  Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation.

Authors:  Julia Meissner; Michael Schmitt; Mindaugas Andrulis; Leonille Schweizer; Sascha Dietrich; Bettina Alber; Inga Harting; Felix T Kurz; Uwe M Martens; Anthony D Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Bone Marrow Transplant       Date:  2022-06-09       Impact factor: 5.174

10.  Natural Killer T Cell Intravascular Lymphoma With Presentation of Musculoskeletal Pain: A Case Report.

Authors:  Shiho Amano; Ryuichi Ohta; Chiaki Sano
Journal:  Cureus       Date:  2021-12-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.